We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is one of the most undervalued stocks to invest in.
TheFly reported on May 27 that IRWD reported that the U.S. Food and Drug Administration expanded the approved use of Linzess to include pediatric patients as young as 2 years old who suffer from functional constipation. Previously, the therapy was authorized for children aged 6 years and older with the same condition. With this updated approval, Linzess can now be prescribed for patients between 2 and 5 years of age, broadening its treatment reach. The company also noted that Linzess remains the only FDA-approved prescription medication available for pediatric functional constipation, reinforcing its position as a key therapy option in this patient population.
Moreover, on May 7, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) reported its financial results for the first quarter of 2026, highlighting improved performance across key metrics. Total revenue reached $106.5 million, compared with $41.1 million in the same period a year earlier. Growth was primarily driven by Ironwood’s share of U.S. LINZESS net sales profits, alongside modest royalties and other income. The company also reported a significant reduction in total expenses to $33.9 million from $70.3 million year over year. GAAP net income was $40.8 million, or $0.25 per share, reversing a prior-year loss. Adjusted EBITDA rose to $76.7 million, compared to a negative result in the prior year period. Cash and liquidity positions also improved modestly.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a biopharmaceutical company focused on developing treatments for gastrointestinal diseases and rare disorders. It is best known for its drug LINZESS.
While we acknowledge the potential of IRWD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
TheFly reported on May 27 that IRWD reported that the U.S. Food and Drug Administration expanded the approved use of Linzess to include pediatric patients as young as 2 years old who suffer from functional constipation. Previously, the therapy was authorized for children aged 6 years and older with the same condition. With this updated approval, Linzess can now be prescribed for patients between 2 and 5 years of age, broadening its treatment reach. The company also noted that Linzess remains the only FDA-approved prescription medication available for pediatric functional constipation, reinforcing its position as a key therapy option in this patient population.
Moreover, on May 7, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) reported its financial results for the first quarter of 2026, highlighting improved performance across key metrics. Total revenue reached $106.5 million, compared with $41.1 million in the same period a year earlier. Growth was primarily driven by Ironwood’s share of U.S. LINZESS net sales profits, alongside modest royalties and other income. The company also reported a significant reduction in total expenses to $33.9 million from $70.3 million year over year. GAAP net income was $40.8 million, or $0.25 per share, reversing a prior-year loss. Adjusted EBITDA rose to $76.7 million, compared to a negative result in the prior year period. Cash and liquidity positions also improved modestly.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a biopharmaceutical company focused on developing treatments for gastrointestinal diseases and rare disorders. It is best known for its drug LINZESS.
While we acknowledge the potential of IRWD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
17 hours ago
